Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
Status:
Completed
Trial end date:
2020-12-25
Target enrollment:
Participant gender:
Summary
The study is a phase 2, multi centered, single arm study designed to evaluate the correlation
between cluster of differentiation 8-positive (CD8+) cell density and objective response rate
in adults with unresected stage IIIB to IVM1c melanoma. This study will also evaluate the
safety and tolerability profile of talimogene laherparepvec.